• 作者：J.A. Monge-Argil&#233 ; s^a ; ^{monge_jos@gva.es} ; J. Sá ; nchez-Payá ; ^b ; C. Muñ ; oz-Ruiz^c ; A. Pampliega-P&#233 ; rez^a ; M.J. Gó ; mez-Ló ; pez^d ; E. Rodrí ; guez Borja^c ; J. Montoya-Guti&#233 ; rrez^a ; C. Leiva-Santana^a
• 关键词：Biomarcadores en LCR ; Deterioro cognitivo leve ; Enfermedad de Alzheimer ; Proteí ; na A¦Â1-42 ; Proteí ; na T-tau ; Proteí ; na P-tau181p
• 刊名：Neurolog¨ªa
• 出版年：2012
• 出版时间：January-February, 2012
• 年：2012
• 卷：27
• 期：1
• 页码：28-33
• 全文大小：211 K

Introduction

Some studies have shown that CSF amyloid-beta 1-42 (A¦Â_1-42), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau_181p) proteins are useful diagnostic markers for distinguishing between clinically stable mild cognitive impairment (MCI) patients and those who will develop Alzheime?s disease (AD).

Our objective was to test the ability of this technique to discriminate in our cohort of MCI patients, according to the clinical outcome, one year after the lumbar puncture.

Material and methods

A total of 36 MCI patients were included from the local hospital memory clinic. Using INNO-BIA Alzbio-3 reagents from Innogenetics, we measured CSF A¦Â_1-42, T-tau and P-tau_181p proteins, and calculated the T-tau/A¦Â_1-42 y P-tau_181p/A¦Â_1-42 ratios. This project was approved by the local ethics committee.

Results

One year after the lumbar puncture, 14 MCI patients (38 % ) developed AD. These patients had lower A¦Â _1-42 protein levels (285.3 vs 377 ng/ml, P < .02) and higher P-tau_181p/A¦Â_1-42 ratio (0,25 vs 0,16, p < .02) than the clinically stable patients.

Conclusions

Our MCI patients with lower A¦Â_1-42 protein levels and an increased P-tau_181p /A¦Â_1-42 ratio progressed quickly to AD. These results may help to identify those MCI patients with a poorer prognosis.